Search Results 191-200 of 7945 for TNF

  1. Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1: Patients who have received acute, low dose, systemic immunosuppressant ...

  2. National Football League Offers Families a Life Line - Mayo Clinic News Network

    The National Football League is teaming with leading experts in crisis intervention, suicide prevention, and mental health messaging and comunications to ...

  3. A Study of Chemotherapy in Patients with Immunoglobulin Light (or Heavy) Chain Amyloidosis - Mayo Clinic

    About this study. The aims of this prospective observational study will be to include all patients with systemic AL amyloidosis regardless of age or disease ...

  4. A Study to Evaluate Chemoradiotherapy with or without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization. Exceptions: Patients may have received acute, low dose, systemic ...

  5. A Study to Evaluate the Safety, Tolerability, and Clinical Benefit of AK002 in Adult Patients with Mast Cell Gastritis and/or Gastroenteritis

    ... TNF, anti-IL-5, anti-IL-5 receptor, dupilumab, anti-IgE antibodies, omalizumab) or systemic corticosteroids with a daily dose >10 mg of prednisone or ...

  6. Publications

    The crosstalk between neuropilin-1 and tumor necrosis factor-alpha in endothelial cells. Front Cell Dev Biol. 2024; 12:1210944 Epub 2024 June 27. View PubMed ...

  7. Guiding Evidence Based Therapy Using Biomarker Intensified Treatment - Mayo Clinic

    Inclusion Criteria: Age 18 years or older; Most recent LVEF to be ≤ 40% by any method within 12 months of randomization. High risk heart failure as defined ...

  8. Center for Computational Biotechnology and Genomic Medicine CCBGM.

  9. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease - Mayo Clinic

    ... tumor necrosis factor alpha (TNFa) antagonists, or vedolizumab. Exclusion Criteria: Current complications of CD such as symptomatic strictures, severe rectal ...

  10. A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis - Mayo Clinic

    methotrexate [MTX]), immunomodulators, and/or tumor necrosis factor alpha (TNF-?) antagonist therapy (eg, infliximab, adalimumab). This includes ...